RudaCure attended the 19th Annual 疼痛治疗 Summit held in 圣迪亚哥 from October 13-14, 2025, gaining insights into the latest changes and research trends in the 疼痛治疗 market. At the event, the company engaged in active networking with major 制药公司 including Eli Lilly, Merck, Roche, and J&J, sharing clinical strategies and 疼痛治疗 market trends.
The summit featured presentations and discussions on the latest research into novel 疼痛治疗药 targets by numerous groups, with a focus on 临床试验 design for pain 药物开发, emerging pain targets, and advanced therapeutics. RudaCure established ongoing networks with companies showing strong interest in its 创新药物 candidate RCI002, creating opportunities to discuss future 对外许可 strategies and technology development directions.
The company is preparing to unveil RCI002 next year and will strengthen collaboration with global 制药公司 to actively pursue 全球市场 expansion.
